Abstract: The invention relates to a long term cell culturing method and a cell culturing apparatus and kit that employ a porous polyimide film. The invention further relates to a cell cryopreservation method and kit employing the porous polyimide film.

Abstract: The present invention provides: a method for producing a mixed sulfonic acid anhydride of the general formula (1) by reacting a sulfonic acid compound of the general formula (2) with a perfluoroalkyl sulfonic acid anhydride or a perfluoroalkyl sulfonic acid halide; and a method for producing a sulfonamide compound of the general formula (4) obtained by reacting an amine compound of the general formula (3) with a mixed sulfonic acid anhydride of the general formula (1).

Abstract: The present invention relates to a cell culturing method as well as a cell culturing apparatus and kit for use in said culturing method. This cell culturing method comprises applying cells on a porous polyimide film and culturing.

Abstract: The present invention relates to a cell culturing method as well as a cell culturing apparatus and kit for use in said culturing method. This cell culturing method comprises applying cells on a porous polyimide film and culturing.

Abstract: The present invention relates to a cell culturing method as well as a cell culturing apparatus and kit for use in said culturing method. This cell culturing method comprises applying cells on a porous polyimide film and culturing. One embodiment of the method according to the present invention comprises a process for sowing cells on the surface of the porous polyimide film. An embodiment comprises a process for placing a cell suspension on the dried surface of the porous polyimide film and leaving the porous polyimide film undisturbed or moving said porous polyimide film to promote liquid efflux or stimulating a portion of the surface to cause the cell suspension to be entangled into the film and then retaining the cells in the cell suspension inside the film while allowing the moisture to flow out.

Abstract: The present invention provides a salt of a substituted pyridine compound which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a salt of a compound represented by general formula (I): wherein R1 is optionally substituted alkoxy or the like.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: The present invention provides a salt of a substituted pyridine compound which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a salt of a compound represented by general formula (I): wherein R1 is optionally substituted alkoxy or the like.

Abstract: A compound represented by formula (1) or salt thereof and a production intermediate thereof are created. The compound exhibited an excellent antioxidation action in a microsome lipid peroxidation measuring system using a rat liver microsome. Therefore, the compound or salt thereof is useful as an antioxidant. The present invention also provides use of a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof for production of an antioxidant.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2, R3, Y, and Z are defined in the specification.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): useful, for example, as an anti-inflammatory agent or an inhibitor of respiratory tract contraction.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: A compound represented by formula (1) or salt thereof and a production intermediate thereof are created. The compound exhibited an excellent antioxidation action in a microsome lipid peroxidation measuring system using a rat liver microsome. Therefore, the compound or salt thereof is useful as an antioxidant. The present invention also provides use of a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof for production of an antioxidant.

Abstract: The present invention relates to a benzazepinone compound represented by the following formula (I): wherein R1 represents a C1-C6 alkyl group or halogeno C1-C6 alkyl group, R2 represents a carboxyl group which may be protected, and Y represents a group represented by the formula (II): wherein Z represents CH or a nitrogen atom, or a pharmaceutically acceptable salt thereof.

Abstract: This is to provide a novel substituted carbonyl compound represented by the following formula (I) having an excellent bronchodilatory action based on potent EP2 agonistic action and useful for treatment of respiratory diseases. A compound represented by the following formula (I): or a salt thereof.

Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.

Abstract: The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independently represent a hydrogen atom or C1-C6 alkyl group, Y represents a bicyclic heteroaromatic ring group which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group, halogeno C1-C6 alkoxyl group and C1-C6 alkylthio group or a group -Q1-Q2 wherein Q1 represents an arylene group or 5- to 6-membered heteroarylene group, Q2 represents an aromatic group or a 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group and halogeno C1-C6 alkoxyl group, Z represents an aromatic group or a 5- to 6-membered heteroaromatic ring group ea

Abstract: An object of the present invention is to create a novel indazole derivative having a spiro ring structure in a side chain, which is useful as a pharmaceutical, and to find a new pharmacological activity of the derivative. The present invention compound is represented by the general formula [I] and has an excellent Rho kinase inhibitory activity. In the formula, the ring X represents a benzene ring or a pyridine ring; R1 and R2 represent halogen, H, OH, alkoxy, cycloalkyloxy, aryloxy, alkyl, cycloalkyl or the like; R3 represents halogen, H or the like; R4 and R5 represent halogen, H or the like; R6 and R7 represent H, alkyl or the like; and m, n, p and q represent an integer of 0 to 3. In this connection, each group may have a substituent.